Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

TLDR

Endometrial carcinoma is the most common uterine malignancy in the U.S., with roughly 65,950 new cases and 12,550 deaths in 2022, encompassing endometrioid, high‑risk histologies, and rare sarcomas. The guideline aims to address the diagnosis, staging, and management of pure endometrioid carcinoma. It details the diagnostic, staging, and management procedures for pure endometrioid carcinoma. The complete NCCN Guidelines for Uterine Neoplasms are available online at NCCN.org.

Abstract

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org.